Xinqi Eye Medicine (300573.SZ): The first subject has been enrolled in the Phase III clinical trial of Lidocaine Hydrochloride Eye Gel.

Zhtng Cijng APP news, Xngq Ynyo (300573.SZ) announced that the company's developed lidocaine hydrochloride eye gel has completed the first subject enrollment for the "Evaluation of the effectiveness and safety of lidocaine hydrochloride eye gel for ocular surface anesthesia through a randomized, double-blind, positive drug parallel control, placebo parallel control, multicenter clinical trial", officially entering phase III clinical trials today.